プロバイオティクスと健康に関するジャーナル
オープンアクセス

概要

A Short Communication on Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention in GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry

Despoina-Rafailia Benetou*, Charalampos Varlamos, Dimitrios Alexopoulos

Patients with Atrial Fibrillation (AF) undergoing percutaneous Coronary Intervention (PCI) represent a high-risk population with an increased ischemic as well as bleeding risk. Aiming to counterbalance thromboembolic risk associated with stent implantation and AF, as well as to mitigate bleeding risk associated with the combination of anthithrombotic drugs, identifying the optimal treatment strategy for this subset of patients remains a challenge in everyday clinical practice [1].